SCHEMBL7121235

SCHEMBL7121235

c1ccc(COCCCNCC2CCc3ccc(OCc4ccccc4)cc3O2)cc1

nearest known ligand 0.81

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7120461 0.94 HTR6 (0.81) HTR6
SCHEMBL7120464 0.94 HTR6 (0.81) HTR6
SCHEMBL7114786 0.93 HTR6 (0.77) HTR6
SCHEMBL7122467 0.93 HTR6 (0.77) HTR6
SCHEMBL7114790 0.93 HTR6 (0.77) HTR6
SCHEMBL7122465 0.93 HTR6 (0.77) HTR6
SCHEMBL7113769 0.92 HTR6 (0.79) HTR6
SCHEMBL7113766 0.92 HTR6 (0.79) HTR6
SCHEMBL7116714 0.91 HTR6 (0.83) HTR6
SCHEMBL7117991 0.90 HTR6 (0.76) HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6638972-B2 Disorders of 5HT-6 receptors WYETH 2003-10-28 US claimed
US-20030153599-A1 Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands WYETH 2003-08-14 US claimed
WO-2003029239-A1 CHROMAN AND BENZOFURAN DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2003-04-10 WO claimed
US-6638972-B2 Disorders of 5HT-6 receptors WYETH 2003-10-28 US disclosed
US-20030153599-A1 Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands WYETH 2003-08-14 US disclosed
WO-2003029239-A1 CHROMAN AND BENZOFURAN DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2003-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153599-A1 Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR1F, HTR1A HTR6 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.